Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the disable-gutenberg domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6121
Phases of the partnership – NGP Neuro

Our ambitions

Attacking diseases in a Holistic and global way - a P2P approach

With this partnership, the NGP will bring about a leap change in the discovery process for brain diseases by harnessing and integrating recent advances in genomics, big data, highly relevant patient derived cellular models, Open Science and the unique patient populations followed at The Neuro and in Canada. The approach will shed light on disease mechanisms, identify new human biology-based targets and accelerate the development of innovative therapies.

Phase 1

Parkinson's disease

The pathogenic process leading to PD begins many years before the diagnosis, which istraditionally based on PD classical motor symptoms. Hence, the course of PD can be divided accordingly, to prodromal PD and clinical PD, when motor symptoms appear. Therefore, one of the most important challenges in PD research is identifying individuals during the prodromal phase of PD, before this extensive irreversible damage has occurred. Studies from recent years have demonstrated that of individuals who present with idiopathic REM sleep behavior disorder, (RBD), more than 80% will progress to PD or other synucleinopathies within 10-12 years on average after the diagnosis of RBD. The majority will convert to PD or dementia with Lewy bodies (DLB). Thus, in the first phase of the NGP, we have a unique opportunity with RBD, to identify patients at a much earlier stage, stratify those that may progress/convert to PD morequickly and test new emerging therapies.

Focus

The initial focus of the NGP will be on prodromal synucleinopathies including Parkinson's Disease (PD) and related syndromes, Dementia with Lewy Bodies (DLB), and Multiple Systems Atrophy (MSA). Protein misfolding disorders associated with Tau and TDP-43 (Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementias (FTDs)), Autism (ASD),Intellectual Deficiency, , and rare neurological diseases (ataxias, HSPs, myopathies) will also be considered as will MS/leukodystrophies and Epilepsy in the future. The disease of focus, types of data delivered, specific cohorts will be identified each year and detailed in the Scientific Program.